# Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

> **NCT05646082** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Imperial College London** · enrollment: 15 (actual)

## Conditions studied

- Refractory HIV Associated Kaposi Sarcoma

## Interventions

- **DRUG:** Dostarlimab in Combination Antiretroviral Therapy

## Key facts

- **NCT ID:** NCT05646082
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-26
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05646082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05646082, "Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05646082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*